Aug 13, 2020
European Medicines Agency Validates BioMarin's Marketing Authorization Application for Vosoritide to Treat Children with Achondroplasia
Jun 17, 2020
BioMarin Provides Additional Data from Recent 4 Year Update of Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A in Late-Breaking Oral Presentation at World Federation of Hemophilia Virtual Summit
Jun 03, 2020
BioMarin to Participate in Two Upcoming Virtual Investor Conferences
May 31, 2020
BioMarin Provides Highlights of 4 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A
May 06, 2020
BioMarin to Participate in Two Upcoming Virtual Investor Conferences
May 03, 2020
BioMarin Extends Gene Therapy Leadership with DiNAQOR in a Preclinical Collaboration and License Agreement to Develop Gene Therapies for Rare Genetic Cardiomyopathies
Apr 29, 2020
BioMarin Announces First Quarter 2020 Total Revenue Growth of 25% to $502 million
Apr 22, 2020
BioMarin Updates Timing of First Quarter 2020 Financial Results Conference Call and Webcast to Wednesday, April 29 at 4:15pm ET
Apr 14, 2020
BioMarin to Host First Quarter 2020 Financial Results Conference Call and Webcast on Thursday, April 30 at 4:30pm ET
Apr 06, 2020
Prime Therapeutics launches PreserveRx(SM) gene therapy financial protection
Apr 06, 2020
BioMarin Plans Regulatory Submissions for Marketing Authorization of Vosoritide to Treat Children with Achondroplasia in 3Q 2020 in both US and Europe
Feb 20, 2020
BioMarin's Biologics License Application for Valoctocogene Roxaparvovec Accepted for Priority Review by FDA with Review Action Date of August 21, 2020
Jan 29, 2020
BioMarin to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call and Webcast on Wednesday, February 26 at 4:30pm ET
Jan 08, 2020
BioMarin to Participate in Goldman Sachs 12th Annual Healthcare CEOs Unscripted: A View from the Top on January 9, 2020 in New York
Jan 08, 2020
Behind the Seizure® Program Further Expands Access to Genetic Testing for Children to Speed the Diagnosis of Genetic Epilepsy
Jan 06, 2020
BioMarin to Present at 38th Annual J.P. Morgan Healthcare Conference in San Francisco
Jan 02, 2020
BioMarin Announces New England Journal of Medicine Publishes 3 Years of Follow-up Data in Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A
Dec 23, 2019
BioMarin Submits Biologics License Application to U.S. Food and Drug Administration for Valoctocogene Roxaparvovec to Treat Hemophilia A
Dec 23, 2019
European Medicines Agency Validates BioMarin's Marketing Authorization Application for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A
Dec 16, 2019
BioMarin Announces Positive Final Results from Placebo-Controlled Phase 3 Data in Children with Achondroplasia Treated with Vosoritide